Trivarx Ltd (ASX:TRI) Share Price & Analysis

TrivarX Limited (ASX: TRI) is an Australia-based healthcare technology company headquartered in Hawthorn East, Victoria, with international operational offices located in Minneapolis, Minnesota. Formerly known as Medibio Limited, the company specializes in developing artificial intelligence-driven, scientifically validated screening and diagnostic devices for behavioral and mental health conditions. TrivarX is listed on the Australian Securities Exchange under the ticker symbol TRI and trades internationally on the OTCQB Venture Market.

The company’s key operations center on proprietary algorithms designed for advanced spectral analyses of sleep architecture and heart rate variability to deliver objective mental health measurements. TrivarX actively advances clinical development programs, including its flagship Stabl-Im trial for brain tumor imaging alongside objective screening tools for depression. Its operational footprint spans clinical trials, scientific research partnerships, and regulatory approval pathways across both Australia and the United States.

TrivarX positions itself as an innovator in objective biometric diagnostics, aiming to address critical limitations in traditional psychiatric screening through data-driven clinical solutions. The company targets healthcare providers, clinical research organizations, and mental health professionals seeking non-invasive tools to support early intervention and monitoring. Its strategic growth focus centers on reaching key clinical trial milestones, expanding its patent portfolio, and commercializing its diagnostic platform across global healthcare markets.